Reports
Reports
Sale
The growth of the continuous renal replacement therapy devices market is driven by the rising number of chronic kidney disease cases, which was about 778.9 million in 2021. The prevalence of the disease is likely to grow at a CAGR of 2.71% during the forecast period of 2023-2031. With this growth rate, the number of cases is likely to reach nearly 990.5 million by 2030.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In February 2021, DaVita achieved a record by adding the secure DaVita Care Connect telemedicine platform to its home dialysis curriculum. As one of many connected technologies, it aims to improve the care experience and outcomes for people who choose home care. Such developments are likely to add significantly to the growth of the global continuous renal replacement therapy devices market.
In December 2020, an emergency cardiac renal paediatric dialysis device was launched by Medtronic plc. Haemodialysis is recommended for patients with acute kidney injury or fluid overload. Patients weighing between 2.5 and 10 kilograms can receive continuous renal replacement therapy devices (CRRT).
In April 2020, during the pandemic, Fresenius Medical Care, a global provider of dialysis facilities and products, issued a notice advocating clinical care for patients with advanced chronic kidney disease. Patients requiring renal replacement therapy during the COVID-19 crisis should receive treatment as determined by their doctor.
In April 2020, it was announced that Baxter International is expanding its worldwide offering of dialysis products. Because of the increase in COVID-19 patients requiring ongoing renal replacement therapy (CRRT), the company experienced extreme demand for multiple acute dialysis products. In order to address these challenges, the company has been working with governments around the world.
An acute kidney injury patient with impaired haemodynamics often requires continuous renal replacement therapy devices (CRRT) a device, for support of the renal function.
The loss or damage of kidney function occurs suddenly within hours or days as a result of acute renal failure (ARF). As a result of kidney injury, waste products build up in the blood and the kidneys can't adequately balance body fluids.
Acute kidney injury can also affect organs, such as the lungs, brain and heart. It is common among patients in hospitals and ICUs, particularly in elders. If it is not treated, this condition can pose a serious risk of organ failure and death.
In addition, the global continuous renal replacement therapy devices market is expected to be driven by the growing cases of diabetes and hypertension as a result of acute kidney injury, the government's commitment to improving medical facilities, and an increase in dialysis facilities.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The one key aspect that accelerate the development of the global kidney dialysis apparatus market is the increase in cases of chronic kidney disease (CKD) among the elderly. It is common for older people to develop kidney failure.
The elderly population is more prone to various diseases due to a weakened immune system and other complications. Diabetes is a common disease that causes many other health problems. Kidney failure is one of the most common health problems caused by diabetes. If it is improperly treated, diabetic patients can develop abnormal kidney function and, in some cases, even complete organ failure. An increased cases of diabetes may increase the risk of growing kidney disease.
The major drivers of the global continuous renal replacement therapy devices market include the rise in demand for procedures, approvals, and new launches of continuous renal replacement therapy devices. The growth of the market is aided by technical progressions in manufacturing.
Manufacturers are now developing precision instruments to ensure safe and reliable performance during kidney replacement therapy procedures. To facilitate operation, these devices are equipped with a modern and intuitive interface.
It is expected that kidney disease will increase the demand for dialysis equipment and encourage manufacturers to develop new products in order to meet this demand.
In addition, the growing demand for home care has prompted manufacturers to focus on developing new and innovative dialysis machines.
As the global market grows, North America is expected to take a significant share. There are several lifestyle-related diseases in the United States, such as diabetes, obesity, hypertension, and other diseases associated with a sedentary lifestyle. That is driving the regional market to grow.
Dialysis equipment market growth will be dominated by the Asia Pacific region. Emerging economies with dense populations will drive market growth in the region. It is because kidney diseases are becoming more prevalent in the region. As patients demand more advanced medical equipment, technological advancements are increasing. The continuous renal replacement therapy devices market is driven by these factors.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
A continuous renal replacement therapy devices is a type of blood purification therapy used in cases of acute kidney disease. The annual average cost of a continuous renal replacement therapy devices machine falls somewhere between USD 10000 to USD 30000. In order to perform continuous renal replacement therapy devices on a patient, these six medical products are required:
Blood Purifier: This device pumps blood, regulates blood flow, and contains software that monitors the safe delivery of therapy.
Dialysate: It is a liquid that removes toxins from the filter.
Fluid Replacement: A special sterile fluid that is used to flush toxins out of the body and replace electrolytes and other blood components.
Filter: Filter has the mechanical component that removes toxins from liquids and urine.
Anticoagulant: Blood clot prevention drug that facilitates blood flow through the system.
Blood Warmer: During blood purification treatment, a blood warmer keeps the patient's blood temperature at an appropriate level.
Emerging Device- In June 2021, A new version of Baxter's next-generation CRRT platform, PrisMax 2, has been released. As part of the TrueVue digital health portfolio, the system offers a new solution for the company. An ongoing continuous renal replacement therapy devices (CRRT) can be delivered more quickly using this technology.
The report gives an in-depth analysis of the top competitors involved in the continuous renal replacement therapy devices market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2016-2022 |
Forecast Period | 2023-2031 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Modality |
|
Breakup Demand by Population |
|
Breakup Demand by Disease Type |
|
Breakup by End-User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Continuous Renal Replacement Therapy Devices Market
4.1 Global Continuous Renal Replacement Therapy Devices Overview
4.2 Global Continuous Renal Replacement Therapy Devices Market Analysis
4.2.1 Market Overview
4.2.1.1 Global Continuous Renal Replacement Therapy Devices Historical Market Value (2016-2022)
4.2.1.2 Global Continuous Renal Replacement Therapy Devices Market Forecast Value (2023-2031)
4.3 Global Continuous Renal Replacement Therapy Devices Market by Product Type
4.3.1 Market Overview
4.3.1.1 Machines
4.3.1.2 Consumables
4.3.1.2.1 Hemofilter Sets
4.3.1.2.2 Solution
4.3.1.2.3 Accessories
4.4 Global Continuous Renal Replacement Therapy Devices Market by Modality
4.4.1 Market Overview
4.4.1.1 Slow Continuous Ultrafiltration (SCUF)
4.4.1.2 Continuous Ven Venous Haemofiltration (CVVH)
4.4.1.3 Continuous Ven Venous Haemodialysis (CVVHD)
4.4.1.4 Continuous Ven Venous Haemodiafiltration (CVVHDF)
4.4.1.5 High-volume Haemofiltration (HVHF)
4.5 Global Continuous Renal Replacement Therapy Devices Market demand by Population
4.5.1 Market Overview
4.5.1.1 Adults
4.5.1.2 Pediatrics
4.6 Global Continuous Renal Replacement Therapy Devices Market demand by Disease Type
4.6.1 Market Overview
4.6.1.1 Acute Kidney Injury
4.6.1.2 Others
4.7 Global Continuous Renal Replacement Therapy Devices Market by End-User
4.7.1 Market Overview
4.7.1.1 Hospitals
4.7.1.2 Dialysis Centres
4.7.1.3 Others
4.8 Global Continuous Renal Replacement Therapy Devices Market by Region
4.8.1 Regional Market Overview
4.8.1.1 North America
4.8.1.2 Europe
4.8.1.3 Asia Pacific
4.8.1.4 Latin America
4.8.1.5 Middle East and Africa
4.9 North America
4.9.1 Historical Trend (2016-2022)
4.9.2 Forecast Trend (2023-2031)
4.9.3 Break Up by Country
4.9.3.1 United States of America
4.9.3.2 Canada
4.10 Europe
4.10.1 Historical Trend (2016-2022)
4.10.2 Forecast Trend (2023-2031)
4.10.3 Break Up by Country
4.10.3.1 United Kingdom
4.10.3.2 Germany
4.10.3.3 France
4.10.3.4 Italy
4.10.3.5 Others
4.11 Asia Pacific
4.11.1 Historical Trend (2016-2022)
4.11.2 Forecast Trend (2023-2031)
4.11.3 Break Up by Country
4.11.3.1 China
4.11.3.2 Japan
4.11.3.3 India
4.11.3.4 ASEAN
4.11.3.5 Australia
4.11.3.6 Others
4.12 Latin America
4.12.1 Historical Trend (2016-2022)
4.12.2 Forecast Trend (2023-2031)
4.12.3 Break Up by Country
4.12.3.1 Brazil
4.12.3.2 Argentina
4.12.3.3 Mexico
4.12.3.4 Others
4.13 Middle East and Africa
4.13.1 Historical Trend (2016-2022)
4.13.2 Forecast Trend (2023-2031)
4.13.3 Break Up by Country
4.13.3.1 Saudi Arabia
4.13.3.2 United Arab Emirates
4.13.3.3 Nigeria
4.13.3.4 South Africa
4.13.3.5 Others
5 Regulations and Current Scenario Evaluation
5.1 Regulatory Capabilities
5.2 Patent Landscape
5.3 Clinical Trials Synopsis (Additional Insight)
6 Industry Dynamics
6.1 Industry Drivers and Constraints
6.2 Porters
6.3 SWOT Analysis
6.4 Key Demand Indicator Analysis
6.5 Key Price Indicator Analysis
6.6 Industry Events, Initiatives, and Trends
7 Supplier Landscape
7.1 Baxter International Inc.
7.1.1 Company Overview
7.1.2 Product Portfolio
7.1.3 Demographic Reach and Achievements
7.1.4 Mergers and Acquisitions
7.1.5 Certifications
7.2 Fresenius Medical care AG and Co. KGaA
7.2.1 Company Overview
7.2.2 Product Portfolio
7.2.3 Demographic Reach and Achievements
7.2.4 Mergers and Acquisitions
7.2.5 Certifications
7.3 NIKKISO Co., ltd.
7.3.1 Company Overview
7.3.2 Product Portfolio
7.3.3 Demographic Reach and Achievements
7.3.4 Mergers and Acquisitions
7.3.5 Certifications
7.4 B.Braun Melsungen AG
7.4.1 Company Overview
7.4.2 Product Portfolio
7.4.3 Demographic Reach and Achievements
7.4.4 Mergers and Acquisitions
7.4.5 Certifications
7.5 Asahi Kasei Corporation
7.5.1 Company Overview
7.5.2 Product Portfolio
7.5.3 Demographic Reach and Achievements
7.5.4 Mergers and Acquisitions
7.5.5 Certifications
7.6 Infomed SA
7.6.1 Company Overview
7.6.2 Product Portfolio
7.6.3 Demographic Reach and Achievements
7.6.4 Mergers and Acquisitions
7.6.5 Certifications
7.7 Medtronic
7.7.1 Company Overview
7.7.2 Product Portfolio
7.7.3 Demographic Reach and Achievements
7.7.4 Mergers and Acquisitions
7.7.5 Certifications
7.8 NxStage Medical, Inc.
7.8.1 Company Overview
7.8.2 Product Portfolio
7.8.3 Demographic Reach and Achievements
7.8.4 Mergers and Acquisitions
7.8.5 Certifications
7.9 Medica S.p.A.
7.9.1 Company Overview
7.9.2 Product Portfolio
7.9.3 Demographic Reach and Achievements
7.9.4 Mergers and Acquisitions
7.9.5 Certifications
7.10 SWS Hemodialysis Care Co., Ltd.
7.10.1 Company Overview
7.10.2 Product Portfolio
7.10.3 Demographic Reach and Achievements
7.10.4 Mergers and Acquisitions
7.10.5 Certifications
7.11 Dialco Medical Inc.
7.11.1 Company Overview
7.11.2 Product Portfolio
7.11.3 Demographic Reach and Achievements
7.11.4 Mergers and Acquisitions
7.11.5 Certifications
7.12 Anjue Medical Equipment Co. Ltd.
7.12.1 Company Overview
7.12.2 Product Portfolio
7.12.3 Demographic Reach and Achievements
7.12.4 Mergers and Acquisitions
7.12.5 Certifications
8 Recommendations and Discussion
9 Continuous Renal Replacement Therapy Devices Distribution Model (Additional Insight)
9.1 Overview
9.2 Potential Distributors
9.3 Key Parameters for Distribution Partner Assessment
The prevalence rate of global continuous renal replacement therapy devices (CRRT) market is likely to grow at a CAGR of 2.71% during the forecast period of 2023-2031.
It is expected that market growth will be fueled by high prevalence of AKI, an increase in ICU patients, and the existence of top competitors focused on developing and marketing technologically advanced CRRT products in the coming years.
North America is accounting in the global market due to the rise in demand for the CRRT treatment market in the United States.
Medtronic, Fresenius Medical care AG and Co. KGaA, Anjue Medical Equipment Co. Ltd., B.Braun Melsungen AG, Infomed SA, are the leading companies in the market.
An acute kidney injury patient with impaired hemodynamics often requires continuous renal replacement therapy devices (CRRT) for support of the renal function.
CRRT is use in people suffering from AKI as a method of blood purification. It involves passing blood through a special filter that removes body fluids and uremic toxins and returns clean blood to the patient.
The dialysate and replacement fluids therapeutic segment offer lucrative growth opportunities.
Renal replacement therapies include hemodialysis (dialysis or peritoneal dialysis), and haemofiltration. These are different methods of blood filtration, both mechanical and non-mechanical.
When the kidneys suddenly lose or damage function within days or hours after an injury is called as acute kidney injury. Waste products build up in the blood after an acute kidney injury, which causes the kidneys to have difficulty maintaining body fluid balance.
The annual average cost of a continuous renal replacement therapy devices (CRRT) device ranges between USD 10000 to USD 30000.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.